Quantitative structure-permeation relationship for iontophoretic transport across the skin.
The objective was to relate the efficiency of a charged drug to carry current across the skin during iontophoresis to its structural and/or physicochemical properties. The corollary was the establishment of a predictive relationship useful to predict the feasibility of iontophoretic drug delivery, and for the selection and optimization of drug candidates for this route of administration. A dataset of 16 cations, for which iontophoretic fluxes have been measured under identical conditions, with no competition from exogenous co-ions, was compiled. Maximum transport numbers correlated with ion mobilities and decreased with ionic size, the dependence indicating that the electromigration mechanism of iontophoresis would become negligible for drugs of hydrodynamic radius greater than about 8 A. Validation of the model was demonstrated by successfully predicting the transport numbers of three structurally distinct dipeptides, the iontophoretic data for which had been determined under distinctly different experimental conditions. Finally, for the "training" set of cations, a strong linear dependence between their transport numbers in skin and those in aqueous solution was demonstrated; the former were larger by approximately a factor of 1.4 consistent with skin's cation permselectivity. In conclusion, this research offers a practical contribution to the development of a predictive structure-transport model of iontophoresis.
Mudry
Blaise
B
School of Pharmaceutical Sciences, Geneva, University of Lausanne, 30 Quai Ernest Ansermet, Geneva 4, Switzerland.
Carrupt
Pierre-Alain
PA
Guy
Richard H
RH
Delgado-Charro
M Begoña
MB
D000279:Administration, Cutaneous; D000818:Animals; D002412:Cations / Q000737:chemistry / Q000378:metabolism*; D003198:Computer Simulation; D004058:Diffusion; D015194:Diffusion Chambers, Culture; D004151:Dipeptides / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D004553:Electric Conductivity; D005240:Feasibility Studies; D007478:Iontophoresis; D008954:Models, Biological; D008956:Models, Chemical; D008970:Molecular Weight; D010539:Permeability; D011487:Protein Conformation; D021281:Quantitative Structure-Activity Relationship; D015203:Reproducibility of Results; D012867:Skin / Q000378:metabolism*; D012869:Skin Absorption; D013552:Swine
D002412:Cations; D004151:Dipeptides
Adv Drug Deliv Rev. 2004 Mar 27;56(5):619-58
15019750
Pharm Res. 1998 Oct;15(10):1579-88
9794501
Physiol Meas. 2004 Jun;25(3):R35-50
15253111
J Pharm Sci. 2006 Mar;95(3):561-9
16419050
Pharm Res. 1990 Mar;7(3):213-21
2339092
Pharm Res. 1991 Sep;8(9):1121-7
1788157
Biophys J. 2006 Apr 15;90(8):2822-30
16443654
Pharm Res. 2001 Dec;18(12):1701-8
11785689
J Control Release. 2001 Jan 29;70(1-2):213-7
11166421
Biol Pharm Bull. 2001 Mar;24(3):278-83
11256485
J Pharm Sci. 2005 Dec;94(12):2667-75
16258982
Eur J Pharm Sci. 2004 Aug;22(5):427-33
15265512
Pharm Res. 2001 Dec;18(12):1714-20
11785691
Pharm Res. 1997 Oct;14(10):1322-31
9358543
J Control Release. 1999 Aug 27;61(1-2):65-9
10469903
J Control Release. 2006 Apr 10;111(3):362-7
16488047
J Control Release. 1999 Apr 19;58(3):323-33
10099157
Pharm Res. 2001 Dec;18(12):1709-13
11785690
J Pharm Sci. 1986 Aug;75(8):738-43
3095533
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):281-305
11259844
Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:35-40
11509905
Biol Pharm Bull. 2001 Jun;24(6):671-7
11411557
J Pharm Pharmacol. 1995 Nov;47(11):883-90
8708980